Stock Research for AZNCF

AZNCF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AZNCF Stock Chart & Research Data

The AZNCF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AZNCF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AZNCF Due diligence Resources & Stock Charts

The AZNCF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AZNCF Detailed Price Forecast - CNN Money CNN View AZNCF Detailed Summary - Google Finance
Yahoo View AZNCF Detailed Summary - Yahoo! Finance Zacks View AZNCF Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AZNCF Trends & Analysis - Trade-Ideas Barrons View AZNCF Major Holders - Barrons
NASDAQ View AZNCF Call Transcripts - NASDAQ Seeking View AZNCF Breaking News & Analysis - Seeking Alpha
Spotlight View AZNCF Annual Report - CompanySpotlight.com OTC Report View AZNCF OTC Short Report - OTCShortReport.com
TradeKing View AZNCF Fundamentals - TradeKing Charts View AZNCF SEC Filings - Bar Chart
WSJ View Historical Prices for AZNCF - The WSJ Morningstar View Performance/Total Return for AZNCF - Morningstar
MarketWatch View the Analyst Estimates for AZNCF - MarketWatch CNBC View the Earnings History for AZNCF - CNBC
StockMarketWatch View the AZNCF Earnings - StockMarketWatch MacroAxis View AZNCF Buy or Sell Recommendations - MacroAxis
Bullish View the AZNCF Bullish Patterns - American Bulls Short Pains View AZNCF Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AZNCF Stock Mentions - StockTwits PennyStocks View AZNCF Stock Mentions - PennyStockTweets
Twitter View AZNCF Stock Mentions - Twitter Invest Hub View AZNCF Investment Forum News - Investor Hub
Yahoo View AZNCF Stock Mentions - Yahoo! Message Board Seeking Alpha View AZNCF Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AZNCF - SECform4.com Insider Cow View Insider Transactions for AZNCF - Insider Cow
CNBC View AZNCF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AZNCF - OTC Markets
Yahoo View Insider Transactions for AZNCF - Yahoo! Finance NASDAQ View Institutional Holdings for AZNCF - NASDAQ


Stock Charts

FinViz View AZNCF Stock Insight & Charts - FinViz.com StockCharts View AZNCF Investment Charts - StockCharts.com
BarChart View AZNCF Stock Overview & Charts - BarChart Trading View View AZNCF User Generated Charts - Trading View




Latest Financial News for AZNCF


What Are AstraZeneca’s Growth Drivers in Fiscal 2018?
Posted on Friday December 14, 2018

How Is AstraZeneca Positioned in December? In the third quarter, AstraZeneca (AZN) managed to surpass consensus adjusted EPS estimates by $0.27. In the third quarter, AstraZeneca reported operating profit of $851 million, which is a YoY decline of 26% on an actual basis and 21% on a constant exchange rate (or CER) basis.


A Look at AstraZeneca’s Expense Projections for Fiscal 2018
Posted on Friday December 14, 2018

How Is AstraZeneca Positioned in December? In the first nine months of 2018, AstraZeneca (AZN) reported selling, general, and administrative (or SG&A) expenses of $7.43 billion, which is a YoY rise of 4% on an actual basis and 1% on a constant exchange rate (or CER) basis. The company reported core SG&A expenses of $6.21 billion in the first nine months of 2018, which is a YoY rise of 10% on an actual basis and 7% on a CER basis.


What Are AstraZeneca’s Margin Projections for Fiscal 2018
Posted on Friday December 14, 2018

How Is AstraZeneca Positioned in December? AstraZeneca (AZN) reported a gross margin of 79.8% in the first nine months of 2018, which is a decline of 200 basis points on a YoY basis. Wall Street analysts expect AstraZeneca to report a gross margin of 80.40% in fiscal 2018, which would be a YoY decline of 39 basis points.


What to Expect from AstraZeneca’s Earnings in Fiscal 2018
Posted on Thursday December 13, 2018

How Is AstraZeneca Positioned in December? In its third-quarter earnings conference call, AstraZeneca (AZN) reiterated its core EPS guidance of $3.30–$3.50 at a constant exchange rate (or CER). In the third quarter, AstraZeneca posted core EPS of $0.71, which is a YoY decline of 37% on an actual basis and 33% on a CER basis.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.